

Sisonke Heterologous mRNA-1273 boost after prime with Ad26.COVS.S (SHERPA study)

An Open-label, phase 3 study to evaluate the effectiveness of heterologous mRNA-1273 boosting of the single or two dose Ad26.COVS.S COVID-19 vaccine among health care workers in South Africa

Study name: Sisonke 4 (SHERPA)

Study number: Sisonke 4 (SHERPA)/ mRNA-1273-P508

Study Sponsor: South African Medical Research Council (SAMRC)

Dear Sisonke 4 / SHERPA participant,

Kindly be advised that the contact details for the South African Health Products Regulatory Authority (SAHPRA) listed in the SISONKE 4 (SHERPA) informed consent form, have changed.

SAHPRA contact details in the consent form:

The Chief Executive Officer
South African Health Products Regulatory Authority
Department of Health
Private Bag X828
PRETORIA
0001
E-mail: Boitumelo.Semete@sahpra.org.za
Tel: (012) 501 0410

New SAHPRA contact details:

The Chief Executive Officer
South African Health Products Regulatory Authority
Loftus Park
Building A
402 Kirkness Street
Arcadia,
Pretoria
0083
E-mail: Boitumelo.Semete@sahpra.org.za
Tel: 012 501 0413